Expectation of life at old age: revisiting Horiuchi-Coale and reconciling with Mitra.

Genus

1International Institute for Applied Systems Analysis, Wittgenstein Centre for Demography and Global Human Capital (IIASA, VID/ÖAW, WU), Schlossplatz 1, 2361 Laxenburg, Austria.

Published: February 2018

Data quality issues at advanced old age, such as incompleteness of registration of vital events and age misreporting, compromise estimates of the death rates and remaining life expectancy at those ages. Following up on Horiuchi and Coale (Population Studies 36: 317-326, 1982), Mitra (Population Studies 38: 313-319, 1984, Population Studies 39: 511-512, 1985), and Coale (Population Studies 39: 507-509, 1985), we examine the conventional approaches to constructing life tables from data deficient at advanced ages and the two adjustment methods by the mentioned authors. Contrary to earlier reports by Horiuchi, Coale, and Mitra, we show that the two methods are consistent and useful in drastically reducing the estimation errors in life expectancy as compared to the conventional approaches, i.e., the classical open age interval model and extrapolation of the death rates. Our results suggest complementing the classical estimates of life expectancy by adjustments using Horiuchi-Coale, Mitra, or other appropriate methods and avoiding the extrapolation method as a tool for estimating the life expectancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797569PMC
http://dx.doi.org/10.1186/s41118-018-0029-7DOI Listing

Publication Analysis

Top Keywords

life expectancy
16
population studies
16
death rates
8
horiuchi coale
8
coale population
8
conventional approaches
8
life
5
expectation life
4
age
4
life age
4

Similar Publications

Hypertensive disorders of pregnancy (HDP) are significant global health issues. This study utilized data from the Global Burden of Disease Study 2021 to analyze trends in incidence, prevalence, and Disability-Adjusted Life Years (DALY) associated with HDP across 204 countries from 1990 to 2021. The analysis employed estimated annual percentage changes and an age-period-cohort model, stratifying data by age, year, geographical region, and sociodemographic index (SDI).

View Article and Find Full Text PDF

Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.

Lancet Oncol

January 2025

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. Electronic address:

Background: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety of CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer and other solid tumours.

View Article and Find Full Text PDF

The pathobiology of neurovascular aging.

Neuron

January 2025

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA. Electronic address:

As global life expectancy increases, age-related brain diseases such as stroke and dementia have become leading causes of death and disability. The aging of the neurovasculature is a critical determinant of brain aging and disease risk. Neurovascular cells are particularly vulnerable to aging, which induces significant structural and functional changes in arterial, venous, and lymphatic vessels.

View Article and Find Full Text PDF

Exploring Caspase-3 overexpression in pheochromocytoma cells: Implications for cancer therapy.

Tissue Cell

January 2025

Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:

Malignant pheochromocytomas are infrequent tumors that have a poorer prognosis compared to their benign counterparts. The administration of chemotherapy to patients with pheochromocytoma can result in adverse side effects and a reduced life quality. Alternative and more targeted treatment strategies, such as gene therapy significantly improve the patients' survival rate and life expectancy.

View Article and Find Full Text PDF

Background: Large, international cohort studies generate high-level evidence, but are resource intense. In end-of-life care such studies are scarce. Hence, planning for future studies in terms of data on screening, recruitment, retention and survival remains a challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!